Secondary Logo

Journal Logo

Brief Communication

Cystoid macular edema in a patient with Danon disease

Mack, Heather G

Author Information
doi: 10.4103/0301-4738.109524
  • Open

Abstract

Danon disease (DD) (Online Mendelian Inheritance in Man 300257) is a rare, X-linked dominant disease characterized by cardiomyopathy, myopathy, and various degrees of mental retardation in males, first reported in 1981.[1]

The genetic locus for DD localizes to the lysosome-associated membrane protein-2 (LAMP2) gene. LAMP-2 protein is found in the lysosomal membrane where it is thought to protect the membrane from proteolytic enzymes and to act as a receptor for proteins imported into lysosomes. In its absence, autophagic vacuoles are seen in the heart and muscles.[23]

Cardiac disease in males is usually severe. In one study of 20 male patients, all patients except one died before 30 years. Implanted pacemakers and defibrillators and heart transplantation have improved life expectancy. Myopathy is typically mild and often asymptomatic. Symptomatic patients present with proximal limb muscle weakness that is slowly progressive. Mild mental retardation affects an estimated 70% of males. Female mutation carriers show a milder phenotype.[4]

Ophthalmic manifestations of DD include in males salt-and-pepper appearance of the midperipheral retina and loss of pigment in the retinal pigment epithelium (RPE) and in females a midperipheral pigmentary retinopathy. Myopia, lens changes, abnormal visual fields, and abnormal electroretinogram have also been described.[45]

Case Report

A 37-year-old man of English descent presented with long-standing photophobia, reduced vision, and retinal pigmentary changes. He had infantile onset dilated cardiomyopathy requiring a cardiac transplant at age 20. He subsequently developed lymphoma in the left kidney, treated by nephrectomy and rituximab, and two bowel lymphomas treated with chemotherapy and rituximab. At age 29, he developed peripheral myopathy when DD was diagnosed on muscle biopsy. He took cyclosporin 100 mg bd, mycophenolate 500 mg bd, ramipril 10 mg daily, amlodipine 10 mg daily, pravastatin 20 mg daily, ezetimibe 10 mg daily, prednisolone 5 mg daily, and aspirin 100 mg daily.

On examination, he was highly myopic; best-corrected Snellen visual acuity (VA) was 20/30 in the right eye and 20/200 in the left eye. Slit-lamp biomicroscopy of the anterior segments was unremarkable. Fundoscopy revealed midperipheral pigmentary changes, with near-complete loss of RPE in the remaining retina. There was no posterior staphyloma in either eye. Cirrus spectral-domain optical coherence tomography (SD-OCT) (Zeiss, Germany) scanning demonstrated asymmetric macular cysts in the inner retinal layers and patchy photoreceptor loss in both maculae [Fig. 1, Table 1]. Humphrey visual field testing (Zeiss, Germany) showed bilateral central scotoma. Ishihara testing demonstrated congenital color deficiency. Full-field ERG testing was performed using a gold foil electrode according to the International Society for Clinical Electrophysiology of Vision standards (LKC Technologies, Inc.). This showed non-specific abnormalities: scotopic responses were of reduced amplitude and normal implicit time; photopic responses were of normal amplitude but increased implicit time. He refused fluorescein angiography.

Figure 1
Figure 1:
Fundus photographs right eye (a), left eye (b), infrared images right eye (c), left eye (d), and horizontal spectral-domain macular OCT scans at baseline right eye (e), left eye (f), and after treatment right eye (g), left eye (h) with oral acetazolamide of a patient with histologically confirmed Danon disease. These demonstrate the peppered pigmentary mottling and cystic-appearing lesions within the macula with photoreceptor loss and minimal response to treatment
Table 1
Table 1:
Retinal thickness and visual function in response to treatment

Treatment with the carbonic anhydrase inhibitor (CAI) dorzolamide 2% topically bd to both eyes was initiated. Following 30 weeks of treatment, the patient reported no change in central vision or glare symptoms. The fundus exams of each eye were similar to that of the baseline visit. There was no significant change in vision, central subfield thickness, or macular cube volume.

He was then treated with acetazolamide 500 mg daily while cyclosporine levels and renal function were monitored. Following 18 weeks of treatment, he reported no change in central vision or glare symptoms. Best-corrected VA was 20/40 in the right eye and CF in the left eye. Fundus exams of each eye were unchanged. Central subfield thickness, macular cube volume, and repeat ERG testing (Roland, Germany) showed no significant changes. He refused further treatments.

Discussion

Danon retinopathy is a rare X-linked disorder related to mutations in the LAMP2 gene. The patient showed characteristic signs of Danon retinopathy and his ERG results were typical of the disease. The patient was myopic, but the macular changes are not typical of pathologic myopic foveoschisis, typically a thickened retina at the posterior pole, with hyporeflective splitting between the outer and inner retina, or of progressive myopic maculopathy, both of which are usually detected in patients with a posterior staphyloma.[67]

Patients with retinal dystrophies have been reported to have both cystoid macular edema (CME) and non-CME macular cysts.[8] The patient refused fluorescein angiography, which is the diagnostic test to differentiate between CME and non-CME cysts, but the asymmetry of cystic changes seen on OCT is typical of CME associated with late hyperfluorescence on intravenous fluoresce in angiography and strongly suggests that the cysts are CME rather than non-CME cysts.[9] The CME is probably due to leakage of fluid through the RPE consequent to failure of the RPE pump. LAMP2 gene is expressed in RPE cells.[5] The reason for abnormal LAMP2 protein resulting in presumed RPE pump failure is not known. To our knowledge, this is the first reported case of CME in histologically confirmed DD.

In our case, topical dorzolamide 2% eye drops and oral acetazomide were not effective in the treatment of CME associated with DD. The reasons for lack of effect may have included low dose of acetazolamide, limited by renal disease; pre-existing photoreceptor atrophy and long-standing visual loss, particularly in the left eye; and pre-existing RPE atrophy, given the mechanism of action of CAI via RPE acidification which helps to enhance chloride transport, and consequently water transport.[10] Also, any non-CME macular cysts may not respond to CAIs.

Lack of effect of CAI is in contrast to previous studies which have demonstrated a beneficial effect of CAIs in patients with retinal dystrophy and CME such as retinitis pigmentosa,[11] and patients with macular cysts, including X-linked retinoschisis and enhanced S-cone syndrome,[8] although some patients fail this treatment. Despite lack of response in our patient, we recommend consideration be given to carbonic anhydrase inhibition for patients with CME associated with Danon retinopathy, given the response seen in other retinal conditions with associated CME and macular cysts with this treatment. A further treatment option to consider for similar patients is intravitreal bevacizumab,[12] which this patient refused.

In conclusion, to our knowledge our patient is the first reported case of Danon retinopathy with CME. Treatment with topical or oral CAI was not effective in this patient. Danon retinopathy is a rare but important retinal dystrophy causing CME. It is suspected in males who have had a cardiac transplant and reduced vision.

1. Danon MJ, Oh SJ, DiMauro S, Manaligod JR, Eastwood A, Naidu S, et al Lysosomal glycogen storage disease with normal acid maltase Neurology. 1981;31:51–7
2. Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, et al Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease) Nature. 2000;406:906–10
3. Sugie K, Noguchi S, Kozuk Y, Arikawa-Hirasawa E, Tanaka M, Yan C, et al Autophagic vacuoles with sarcolemmal features delineate Danon disease and related myopathies J Neuropathol Exp Neurol. 2005;64:513–22
4. Prall FR, Drack A, Taylor M, Ku L, Olson JL, Gregory D, et al Ophthalmic manifestations of Danon disease Ophthalmology. 2006;113:1010–3
5. Schorderet DF, Cottet S, Lobrinus JA, Borruat FX, Balmer A, Munier FL. Retinopathy in Danon disease Arch Ophthalmol. 2007;125:231–6
6. Gaucher D, Haouchine B, Tadayoni R, Massin P, Erginay A, Benhamou N, et al Long-term follow-up of high myopic foveoschisis: Natural course and surgical outcome Am J Ophthalmol. 2007;143:455–62
7. Hayashi K, Ohnu-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, et al Long-term pattern of progression of myopic maculopathy Ophthalmology. 2010;117:1595–611
8. Ganesh A, Stroh E, Manayath GJ, Al-Zuhaibi S, Levin AV. Macular cysts in retinal dystrophy Curr Opin Ophthalmol. 2011;22:332–9
9. Hirakawa H, Iijima H, Gohdo T, Tsukahara S. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa Am J Ophthalmol. 1999;128:185–91
10. Strauss O. The retinal pigment epithelium in visual function Physiol Rev. 2005;85:845–81
11. Genead MA, Fishman GA. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and Usher syndrome Arch Ophthalmol. 2010;28:1146–50
12. Yuzbasioglu E, Artunay O, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa Curr Eye Res. 2009;34:231–7

Source of Support: Nil

Conflict of Interest: None declared.

Keywords:

Carbonic anhydrase inhibitor; Danon disease; ERG; retinal disease; SD-OCT

© 2014 Indian Journal of Ophthalmology | Published by Wolters Kluwer – Medknow